This coverage milestone significantly broadens the addressable patient population for TONMYA, a key catalyst for revenue ramp. Monitor prescription data and upcoming quarterly earnings for evidence of conversion. Sales force expansion ahead of the Jan 1, 2027 effective date suggests management expects accelerating demand. Positive read-through for the commercial execution thesis.
Price Chart
Executive Summary
Tonix announced a major Medicare Part D payer agreement for TONMYA, adding approximately 9 million Medicare lives (16% of U.S. Medicare) effective January 1, 2027. Combined with prior commercial and Medicaid coverage, total access will reach ~145 million lives (46% of covered lives). The company is also expanding its sales force to 150 representatives by mid-Q3 2026, signaling confidence in the launch trajectory.
Key Facts
- New Medicare PBM agreement adds ~9 million Medicare Part D lives effective Jan 1, 2027
- Total TONMYA coverage to reach ~145 million lives (46% of 314 million covered lives) by Jan 1, 2027
- Medicaid already covers ~73 million lives in most states
- Two prior commercial payer agreements through GPOs effective Q2 2026
- Sales force to expand from ~100 to ~150 representatives by mid-Q3 2026
- TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years (approved Aug 15, 2025)
Financial Impact
No specific revenue or financial impact quantified in the filing; coverage expansion is expected to drive future prescription volume and revenue growth.
Risk Factors
- Coverage does not guarantee prescription uptake; physician adoption and patient conversion remain uncertain
- Competition from existing fibromyalgia treatments (e.g., Lyrica, Cymbalta, Savella) may limit market share
- Delays in sales force deployment or payer contracting could slow momentum
- Patent exclusivity only until 2034; generic or biosimilar threats may emerge
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-032925 |
| Exhibit: ex99-01.htm | 0001493152-26-032925 |
| Document: 0001493152-26-032925-index-headers.html | 0001493152-26-032925 |
| Document: 0001493152-26-032925-index.html | 0001493152-26-032925 |
| Document: 0001493152-26-032925.txt | 0001493152-26-032925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers